Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276601 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00276601: Completed Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00276601 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00276601, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy works in treating patients with acute promyelocytic leukemia.
Interventions
- DRUG mercaptopurine
- DRUG methotrexate
- DRUG cytarabine
- DRUG daunorubicin hydrochloride
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT00276601 record still lists
NCT00276601 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which mercaptopurine is the first listed.
NCT00276601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00276601 about?
NCT00276601 is a clinical study titled "Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving c...
What is the current status of trial NCT00276601?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00276601?
The interventions under investigation include: mercaptopurine (DRUG), methotrexate (DRUG), cytarabine (DRUG), daunorubicin hydrochloride (DRUG), arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00276601?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia